Alcon Research, Ltd.

Panoptica, Inc.

Other

Alcon, Inc.

The Schepens Eye Research Institute, Inc.

Arrowhead Pharmaceuticals, Inc.

Arrowhead Research Corporation

David P Bingaman

Martin B Wax

Jon E Chatterton

Paul G Chaney

Abbot F Clark

Adrian M Timmers

Mark R Hellberg

Peter G Klimko

Daniel A Gamache

Andrius Kazlauskas

Magdalena Staniszewska

Carmelo Romano

Robert Landers

The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.

Ocular formulations for drug-delivery to the posterior segment of the eye

The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.

Ocular formulations for drug-delivery and protection of the anterior segment of the eye

RNA interference is provided for inhibition of tumor necrosis factor &#x3b1; (TNF&#x3b1;) by silencing TNF&#x3b1; cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF&#x3b1; converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF&#x3b1; targets, in particular, is useful for treating patients having a TNF&#x3b1;-related condition or at risk of developing a TNF&#x3b1;-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.

RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis

RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis

RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis

RNA interference is provided for inhibition of tumor necrosis factor &#x3b1; (TNF&#x3b1;) by silencing TNF&#x3b1; cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF&#x3b1; converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF&#x3b1; targets, in particular, is useful for treating patients having a TNF&#x3b1;-related condition or at risk of developing a TNF&#x3b1;-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.

RNAi-related inhibition of TNF&#x3b1; signaling pathway for treatment of glaucoma

RNAi-related inhibition of TNF&#x3b1; signaling pathway for treatment of ocular angiogenesis

The invention provides methods and compositions for identifying and quantifying pathological changes on the retina.

Compositions and methods for treatment of angiogenesis-associated ocular disorders

RNAi-mediated inhibition of H1F1A for treatment of ocular angiogenesis

Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed.

5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses

Growing community of inventors

Weatherford, TX, United States of America

David P Bingaman